You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205091 - 205100 of 207712 results
  1. RAPID POINT OF CARE DIAGNOSTIC TEST FOR HISTOPLASMOSIS

    SBC: ZYMERON CORPORATION            Topic: 86

    Histoplasmosis is the most common endemic fungal infection in North America and in certain areas of Mexico and Central and South America. In the United States, of the endemic mycoses, histoplasmosis was the most common cause for hospitalization and death. Histoplasmosis can cause a wide spectrum of manifestations that range from subclinical infections to more severe progressive disseminated diseas ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A NOVEL HIV VACCINE CO-DELIVERY SYSTEM: AN INJECTABLE THERMOSENSITIVE HYDROGEL ENCAPSULATING POLYROTAXANE

    SBC: ZYMERON CORPORATION            Topic: 77

    Self-amplifying mRNA (saRNA) vaccines offer several advantages. Compared with HIV protein vaccines, they can be rapidly produced with reduced development time and costs by using a common manufacturing platform and purification methods. The antigen would be expressed in situ, allowing for transmembrane domains and multimeric complexes to be formed and more naturally presented to the immune system t ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. RAPID POINT OF CARE TESTS TO QUANTIFY HEPATITIS C VIRUS

    SBC: ZYMERON CORPORATION            Topic: 99

    To develop diagnostics for Hepatitis C.

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. THE OBJECTIVE OF THIS CONTRACT IS TO DESIGN, SYNTHESIZE COMPOUNDS THAT BIND TO NEF, AN HIV ACCESSORY PROTEIN.

    SBC: ZYMERON CORPORATION            Topic: 88

    Therapeutic Targeting of Intracellular HIV-1 Proteins or Nucleic Acids: This research topic supports the development of therapeutics which target intracellular HIV proteins or nucleic acids (DNA, RNA) with the goal of inhibiting their function and ultimately HIV replication. The objective of this contract is to design and synthesize compounds that bind to Nef, an HIV accessory protein, which will ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. THE CONTRACTOR SHALL PROPOSE NOVEL, LOW-COST, REAL-TIME POINT-OF-CARE (POC) ASSAYS FOR HIV VIRAL LOAD MONITORING, HIV DRUG RESISTANCE MONITORING, AND

    SBC: ZYMERON CORPORATION            Topic: 87

    The goal is to develop novel, low-cost, real-time point-of-care (POC) assays for antiretroviral drug adherence monitoring: - Rapid point-of-care methods that measure long-term (rt 7 days) adherence to antiretroviral drugs - Ability to measure drug levels in various biological matrices, e.g., urine, hair, dried blood spots, etc. - Ability to monitor PrEP adherence, ART adherence to trigger adherenc ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. THE CONTRACTOR SHALL DEVELOP A NOVEL NANOPARTICLE DELIVERY SYSTEM TO ELICIT POTENT AND LONG-LASTING ANTIBODY RESPONSE AND BROADLY NEUTRALIZING ACTIVIT

    SBC: ZYMERON CORPORATION            Topic: 89

    Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. RAPID POINT OF CARE TESTS TO SIMULTANEOUSLY QUANTIFY ANTI-TB DRUGS IN BLOOD.

    SBC: ZYMERON CORPORATION            Topic: 74

    Development of a rapid, low-cost, point-of-care (POC) lateral flow test to measure multiple TB drug concentrations simultaneously in human blood.

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. ORODISPERSIBLE FILM OF SECOND LINE DRUG FOR PEDIATRIC TUBERCULOSIS TREATMENT.

    SBC: ZYMERON CORPORATION            Topic: 97

    To develop tuberculosis therapeutic formulations for pediatric patients.

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR TOPIC 441.ZYMERON WILL DEVELOP USER-FRIENDLY TECHNOLOGIES AND DEVICES TO CREATE AN AT-HOME HEPATITIS C VIRUS TEST.

    SBC: ZYMERON CORPORATION            Topic: 441

    Zymeron aims to develop user-friendly technologies and devices to achieve Hepatitis C Virus (HCV) testing at home. Without special training required, anyone can prepare an HCV RNA sample from fingerprick blood for subsequent isothermal amplification and paper-based nanoenhanced sensitive detection just by following simple instructions. The two innovations that Zymeron will develop to achieve such ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. RAPID POINT OF CARE TEST TO SCREEN HUMAN PAPILLOMAVIRUS IN LOW-RESOURCE SETTINGS

    SBC: ZYMERON CORPORATION            Topic: 451

    Cervical cancer caused by human papillomavirus (HPV) is the fourth most common cancer among women worldwide, but it is preventable by screening asymptomatic women before HPV infection progresses to an invasive disease. The screening programs in developed countries use the cytology-based approach (Pap testing) followed by colposcopy, which require a high degree of organization and management. They ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government